Skip to main content

Autolus Therapeutics plc (AUTL) Stock Forecast

Data as of Aug 7, 2026

Healthcare · Current price $1.96 (+2.63%)

Consensus Target
$8.87
Upside
+485.5%
Analysts
4
Rating
Buy(2.00)

Price Target Range

Low $7.60Consensus $8.87High $11.00
▲ Current $1.96

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

AUTL vs Sector & Market

MetricAUTLHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count4818
Target Upside+485.5%+16315.6%+17.2%
P/E Ratio-1.373.4135.26

Revenue Estimates

PeriodLowAvgHigh#
2027-03-31$36M$37M$39M2
2027-06-30$40M$41M$44M2
2027-09-30$43M$45M$47M2
2027-12-31$47M$49M$51M2
2028-03-31$58M$61M$64M1
2028-06-30$62M$65M$69M1
2028-09-30$67M$70M$74M1
2028-12-31$73M$77M$81M1

EPS Estimates

PeriodLowAvgHigh#
2027-03-31$-0.22$-0.21$-0.201
2027-06-30$-0.21$-0.20$-0.181
2027-09-30$-0.20$-0.18$-0.171
2027-12-31$-0.19$-0.17$-0.161
2028-03-31$-0.21$-0.20$-0.192
2028-06-30$-0.20$-0.19$-0.182
2028-09-30$-0.19$-0.18$-0.172
2028-12-31$-0.18$-0.17$-0.162

Frequently Asked Questions

What is the analyst consensus for AUTL?

The consensus among 4 analysts covering Autolus Therapeutics plc (AUTL) is Buy with an average price target of $8.87.

What is the highest price target for AUTL?

The highest analyst price target for AUTL is $11.00.

What is the lowest price target for AUTL?

The lowest analyst price target for AUTL is $7.60.

How many analysts cover AUTL?

4 analysts have issued ratings for Autolus Therapeutics plc in the past 12 months.

Is AUTL a buy or sell right now?

Based on 4 analyst ratings, AUTL has a consensus rating of Buy (2.00/5) with a +485.5% upside to the consensus target of $8.87.

What are the earnings estimates for AUTL?

Analysts estimate AUTL will report EPS of $-0.21 for the period ending 2027-03-31, with revenue estimated at $37M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.